Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 reporting that director Melinda Brown purchased 1,682 common shares on June 25 2025 at a weighted-average price of $4.14–$4.15. Following the transaction, Brown’s direct beneficial ownership increased to 20,565 shares.
No other non-derivative or derivative transactions were disclosed, and there were no sales. The filing contains a standard footnote explaining the weighted-average price range. No 10b5-1 trading plan box was checked.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 disclosing that director Kevin Buehler purchased 5,076 shares of common stock on 25 Jun 2025 at a weighted-average price of $4.16 per share (trade range: $4.16–$4.18). After the transaction, Buehler directly owns 28,137 shares, an increase of roughly 22% in his personal stake. The transaction was coded “P” for an open-market purchase, and the filing reports no sales or derivative security activity. No Rule 10b5-1 trading plan was indicated.